Article Text

Download PDFPDF
P78 Can Pet Standard Uptake Variable (suv) Predict Disease Progression In Early-stage Non-small Cell Lung Cancer (nsclc)?
  1. FJ Frost,
  2. GH Jones,
  3. J Greenwood,
  4. M Ledson,
  5. MJ Walshaw
  1. Liverpool Heart and Chest Hospital, Liverpool, UK


Introduction The correlation between SUV on PET-CT and prognosis in NSCLC has been the subject of much debate. We were interested in whether SUVmax values could be used to determine which cases of early stage (1–2) NSCLC were likely to progress.

Methods We reviewed all 93 histologically proven early stage NSCLCs seen at our tertiary centre over a one year period. We defined those with SUVmax in the upper quartile as the high SUV group and compared these with the remainder. Historical data were considered to allow subsequent outcomes to be established.

Results Median follow up was 772 days during which time there was a 17% mortality rate [all-cause median time to death 338 days]. The median SUVmax for the cohort was 10.1, and those in the upper quartile all had results over 15.0.

The high SUVmax group (n = 27) and low SUVmax group (n = 68) had similar baseline characteristics, received similar treatment regimens and there were no significant differences in tumour size between the groups. Disease progression and mortality were both significantly higher in those with SUVmax in the upper quartile, despite this group tending to have earlier disease (see Table 1).

Retrospective analysis using Youdin’s index suggested that the optimal threshold for predicting disease progression was not significantly different when cases with nodal involvement were excluded [SUVmax 15.0 vs 15.5]

Conclusions Our results suggest that SUVmax may indeed help identify those patients with early stage NSCLC at higher risk of progression. In our large cohort those with an SUVmax of >15 were over 3 times more likely to develop progressive disease than those with lower results and this was independent of tumour size or nodal involvement. Whether individuals in the higher-risk group would benefit from increased surveillance or adjuvant therapy remains to be established.

Abstract P78 Table 1

Early stage NSCLC

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.